MMP9 and neoplasm: In the orthotopic TNBC mouse model, the cRGD-lipo-LGAL-treated group showed reduced tumor growth and lung metastasis, accompanied by suppressing TAK1 activation and MMP9 expression, compared to those in the cRGD-lipo control group (Fig. 8).